Psoriatic arthritis causes severe joint pain owing to the buildup of crystals of uric acid in the joint. Intense pain and redness of the joints are some of the signs of gouty arthritis. With the aid of medicine, this disease can be cured. As a result of excessive consumption or the body's inability to metabolize it, uric acid deposits in joints such as ankles, toes, and wrists, causing inflammation. As uric acid crystals accumulate in the kidneys, untreated gouty arthritis can cause damage to joints and kidneys. There are other metabolic illnesses or ailments such as hypertension, obesity, and diabetes that are associated with it.
Hypertension, for example, is commonly related to gout. Around 75% of gouty arthritis patients had hypertension, according to research published in the Journal of Rheumatology in 2014. Chronically ill people are therefore at a higher risk of acquiring gouty arthritis. It is predicted that the increasing incidence of gouty arthritis would fuel the global gouty arthritis market's expansion. Worldwide, 1 to 10% of people have gouty arthritis, according to research published in the British Medical Journal last year. Additionally, the rising consumption of high protein food worldwide, linked to gouty arthritis, and increasing awareness among people regarding the early treatment of the disease have been factors driving the growth of the gouty arthritis market.
Unawareness by physicians about effective treatment of the illness, especially in emerging nations poses a barrier to gouty arthritis market growth, especially in emerging economies. A urate-lowering drug reduces serum urate levels for the breakdown of urate crystals either by reducing serum uric acid synthesis or by increasing its excretion, for example. En outre, gouty arthritis market growth is hindered by the high costs associated with medical therapy for chronic gouty arthritis.
Takeda Pharmaceutical Company Ltd., Novartis AG, GlaxoSmithKline plc, Merck& Co. Inc., Teijin Pharma Ltd., Regeneron Pharmaceuticals, JW Pharmaceutical Corporation, and Nippon Chemiphar Co. Ltd. are some of the major competitors in the gouty arthritis industry today.